… High-affinity inhibition is mediated by the sulphonylurea receptor, whereas low-affinity
block may involve direct drug interaction with Kir6.2. The maximum drug level measured in …

… as candidate interacting precipitants. We first predicted the drug–drug interaction potential
based on the pharmacokinetics of each secretagogue–precipitant pair. We then performed …

… It is not only the absolute level of insulin secreted that is important. We know that insulin
release following an acute secretagogue challenge occurs as a rapid early-phase response that …

… Although the company decided not to continue the development of this compound, recent
publications reported the potential of PKs and (pharmacodynamics) PD drug–drug interactions …

… tifying Drug–Drug Interactions: Application to Insulin Secretagogues” … In this study,
discontinuation of an insulin secretagogue … drug pairs for which there is a known potential …

… Since a review on drug interactions of clinical importance with … new insulin secretagogues
(compounds of the meglitinide family, ie nateglinide and repaglinide) and new insulin …

… They are short-acting insulin secretagogues and are associated with less risk of hypoglycemia,
weight gain and chronic hyperinsulinemia compared with sulfonylureas. Meglitinides are …

… These second-generation agents are nonionically bound to plasma proteins, making them
less vulnerable to drug–drug interactions and less likely to compete with other drugs for …

… The therapeutic approach to this problem has been to administer drugs that enhance
insulin secretion insulin secretagogues) or delay the absorption of the meal a-glucosidase …

… associated to T2DM, drug interactions, namely pharmacokinetic and pharmacodynamic …
are less likely to induce hypoglycemia compared to other insulin secretagogues (ie …